Slide 1: Compass Therapeutics Investor Call
Compass Therapeutics (Nasdaq: CMPX) Investor Call January 23, 2023
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the
Slide 3: Overview of CTX-009
Overview of CTX-009 ➤ Bispecific antibody blocking VEGF-A (soluble ligand) and DLL4 (Notch-1 ligand) ➤ Does not lead to ADCC, Fc inactive ➤ Binds to its targets with 2:2 valency ➤ At 10 mg/Kg, CTX-009 has approximately the same VEGF-A capturing ability as bevacizumab (Avastin) ➤ The only VEGF X DLL4
Slide 4: Phase 2 CTX-009 Combination Study (S. Korea)
Phase 2 CTX-009 Combination Study (S. Korea) Patients with biliary tract cancers after one or two prior therapies Simon 2 Stage adaptive design Stage 1 Stage 2 CTX-009 at 10 mg/kg biweekly CTX-009 at 10 mg/kg biweekly Paclitaxel 80 mg/m2 weekly 3 of 4 weeks 3 or Paclitaxel 80 mg/m2 weekly 3 of 4 wee
Slide 5: Phase 2 CTX-009 Combination Study – Patient Demographics
Phase 2 CTX-009 Combination Study – Patient Demographics 24 Total Patients 24 Total Patients Age Prior systemic therapies, n(%) Median (years) 61.5 1 11 (46%) Gender, n(%) 2 13 (54%) Male 14 (58%) Prior Gem/Cis regimen 23 (96%) Female 10 (42%) BTC subtype, n (%) ECOG performance status, n(%) Intrahe
Slide 6: Phase 2 CTX-009 Data: Percent tumor decline
Phase 2 CTX-009 Data ORR = 37.5% Responses achieved across multiple BTC subclasses. Data as of November 9, 2022 CBR = 91.5% Patient Number CONFIRMED PARTIAL RESPONSE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 0 -1 -10 -7 -7 -9 -12 -12 -12 Percent tumor decline -17 -17 -20 -19 -20 -25 -
Slide 7: Swimmer Plot (November 9, 2022 data cut off)
Swimmer Plot (November 9, 2022 data cut off) C1D1 to EOT (Days) 0 100 200 300 400 500 600 700 580 511 343 324 316 310 303 297 287 277 183 182 175 173 PR SD PD 168 Death On-going 159 119 119 93 92 78 58 52 49 7
Slide 8: CTX-009 Phase 2 Results (Median follow-up of 12.1 months)
CTX-009 Phase 2 Results (Median follow-up of 12.1 months) • 24 patients enrolled and dosed • 1 patient remains on study Number of previous ORR systemic therapies Endpoint Value (95% CI) Overall Response Rate (ORR) 37.5% Pts treated in 7/11 (63.6%) the 2L [n=11] Stable Disease (SD) 54.2% Pts treated
Slide 9: Secondary Endpoints: PFS and OS
Secondary Endpoints: PFS and OS (as of Nov 9, 2022) • Median PFS: 9.40 m (5.4-11.1) • Median OS: NA (12.5-NA) A B 1.0 1.0 + Censored + Censored 0.9 Group Median(95% CI) 0.9 Group Median(95% CI) All All 12.5(10.9-NA) 9.4(5.4-11.1) 0.8 0.8 2nd line 11.7(9.1-NA) 2nd line 10.0(5.1-NA) 0.7 3rd line 12.9(
Slide 10: Treatment-Emergent ≥ Grade 3 Adverse Events (>10% of patients)
Treatment-Emergent ≥ Grade 3 Adverse Events (>10% of patients) Phase 2 BTC study of CTX-009 plus paclitaxel Bevacizumab and paclitaxel label information Event 24 total Patients N (%) Bevacizumab Paclitaxel Event (label) (label) Neutropenia 20 (83.3%) Neutropenia 52% Anemia 5 (20.8%) Hypertension 5-1
Slide 11: CTX-009 Interim Phase 2 Study Summary
CTX-009 Interim Phase 2 Study Summary 24 patients with BTC have been Other regimens in BTC enrolled and dosed 10 partial responses (PRs) for a 37.5% ORR in FOLFOX (NCCN guidelines): patients treated in the second- and third-line 5% ORR in the second-line setting settings (64% ORR of patients treated
Slide 12: Phase 2/3 U.S. BTC Study Design
Phase 2/3 U.S. BTC Study Design Patients who have received one prior line of therapy Study Treatment Follow Up CTX-009 + Paclitaxel 28 Day Cycles 2:1 Randomization n=100 CTX-009 10mg/kg Disease Progression Death, Lost to Day 1 and 15 per RECIST 1.1, as Follow Up, Paclitaxel 80 mg/m2 confirmed by Wit
Slide 13: CTX-009: BTC Patient Demographics and Current Treatments
CTX-009: BTC Patient Demographics and Current Treatments US EU5 Japan Worldwide Incident 18,4001 21,8002 14,3292 >200,0003 Cases 1L Treatment 2L Treatment Doublet chemo of gemcitabine + FOLFOX FGFR2 mutation IDH1 mutation MSI-H tumors Clinical trial cisplatin (ABC-02 study) 5% ORR Pemigatinib Ivosid
Slide 14: Phase 1a CTX-009 Monotherapy Data
Phase 1a CTX-009 Monotherapy Data Clinical activity at RP2D dosages (10 and 12.5 mg/kg) Median Time to Prior VEGF Partial Response Stable Disease Clinical Benefit Rate Progression (TTP) Targeted Therapy (PR) (SD) (PR + SD) (Months) All patients (n=16) 75% 19% 50% 69% 3.9 Colorectal Cancer (n=6) 100%
Slide 15: Phase 2 U.S. CRC Study Design
Phase 2 U.S. CRC Study Design Simon 2 Stage Adaptive Design n = 37 subjects Stage 1 No Stop Recruitment ORR > 3/37 Yes Stage 2 n = 47 subjects 15
Slide 16: CTX-009: CRC Patient Demographics and Current Treatments
CTX-009: CRC Patient Demographics and Current Treatments US EU5 Japan Worldwide 153,0201 246,7342 148,5052 1,931,5902 Incident Cases ~50% Metastatic3 38,000-53,000 50-70% reach 3L4 patients 1L Treatment 2L Treatment 3L Treatment Chemotherapy Bevacizumab or Anti-PD-1 with Bevacizumab or BRAF/EGFR wit
Slide 17: CTX-009 Development Plans
CTX-009 Development Plans Initiated Q4 2022 Initiated Q1 2023 Initiate H2 2023 Phase 2 Phase 2 study in third- and fourth- study in advanced Phase 2/3 ovarian or other cancer line colorectal cancer in Randomized BTC in the US the US study in the US Evaluating additional indications for CTX-009 both
Slide 18: Dr. Richard M. Goldberg
Dr. Richard M. Goldberg Professor and Director Emeritus The West Virginia University Cancer Institute
Slide 19: How Does CTX-009 Data Compare to Other BTC Studies?
How Does CTX-009 Data Compared to Other BTC Studies? CTX-009 FOLFOX (ABC-06) 1 Gem/Cis 2 Gem/Cis + Durv 3 Mixed 2L and 3L Only 2L 1L Only 1L Parameter N=24 N=81 N=204 N=341 ORR 37.5% [64% 2L; 15% 3L] 5% 26% 26.7% OS 12.5 m 6.2 m 11.7 m 12.9 m PFS 9.4 m 4.0 m 8.0 m 7.2 m Any AE 100% 99% 55% 99.4% Gr
Slide 20: Q&A
Q&A